We usually think of bodily sensations as information the brain receives. What if the way we attend to those sensations can feed back and change the biological response itself?

Attention is already known to shape how bodily sensations are perceived. Focusing away from pain or itch, for example, can make these sensations feel less intense. A new study from the lab of Dr. Liron Rozenkrantz at Bar-Ilan University’s Azrieli Faculty of Medicine, published today in Nature Human Behaviour, shows that attention can also influence the body’s inflammatory response.

Researchers have discovered a new genus and species of underground earthworm eel living beneath the Indo-Gangetic Plain in Bihar, northern India. The small, colourless creature, named Gangaichthys indonepalicus, is the first subterranean fish to be recorded from the Gangetic Basin.

A new study at the Department of Anatomy and Anthropology of Tel Aviv University, and published in Scientific Reports, offers an explanation for one of the striking differences between men and women: the evolutionary development of the modern human pelvis. By comparing Neandertal pelvises with those of modern humans, the researchers reached a surprising conclusion: the unusual structure of the pelvis may not be that of the Neandertal, as has been assumed for decades, but rather that of the modern human male. According to the researchers, the male pelvis evolved into a unique biomechanical shock absorbing mechanism that stores energy and makes long-distance walking more efficient.

ARDD 2026 has announced that Adiv Johnson, Ph.D., Chief Scientific Officer at Tally Health, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Christophe Weber, former CEO of Takeda, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Kan Chen, Ph.D., Co-Head of Healthcare and Partner at Qiming Venture Partners, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.